Sign in to view content

Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER

Carl D. Regillo, MD

Video
Published 2020

Related

Aflibercept Versus Vitrectomy With Panretinal Photocoagulation for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy
Hani Salehi-Had, MD, FASRS
On Demand Cases, Courses, and Papers
2021
Impact of Delayed Treatment in Diabetic Retinal Disease: Experience From VISTA/VIVID and PANORAMA
Sunil Srivastava, MD
Annual Meeting Talks
2021
PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration
David T.W. Wong, MD, FRCS(C), FASRS
Updates from the Field
2025

Category: AMD-Neovascular

See more